title: 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.
abstract: To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines of treatment in advanced disease, early-stage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on first line/second and further lines of treatment in advanced disease.
authors.affiliation: Thoracic Group, Department of Cancer Medicine, Gustave Roussy, Villejuif, France clinicalguidelines@esmo.org.
authors.forename: B
authors.initials: B
authors.lastname: Besse
authors.affiliation: Medicine Oncology, Roswell Park Cancer Institute, Buffalo, USA.
authors.forename: A
authors.initials: A
authors.lastname: Adjei
authors.affiliation: The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
authors.forename: P
authors.initials: P
authors.lastname: Baas
authors.affiliation: Aarhus University Hospital, Aarhus, Denmark.
authors.forename: P
authors.initials: P
authors.lastname: Meldgaard
authors.affiliation: Aberdeen Royal Infirmary Anchor Unit, Aberdeen, UK.
authors.forename: M
authors.initials: M
authors.lastname: Nicolson
authors.affiliation: Hospital Universitario Virgen del Rocio, Sevilla, Spain.
authors.forename: L
authors.initials: L
authors.lastname: Paz-Ares
authors.affiliation: Department of Thoracic Oncology, Krankenhaus Grosshansdorf, Grosshansdorf, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Reck
authors.affiliation: Department of Pulmonary Diseases, Vrije University Medical Centre (VUMC), Amsterdam, The Netherlands.
authors.forename: E F
authors.initials: EF
authors.lastname: Smit
authors.affiliation: Oncology Unit, Third Department of Medicine, Athens Chest Hospital Sotiria, Athens, Greece.
authors.forename: K
authors.initials: K
authors.lastname: Syrigos
authors.affiliation: Clinic of Oncology, University Hospital Zürich, Zürich, Switzerland.
authors.forename: R
authors.initials: R
authors.lastname: Stahel
authors.affiliation: Medical Oncology, Vall D'Hebron University Hospital, Barcelona, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Felip
authors.affiliation: Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
authors.forename: S
authors.initials: S
authors.lastname: Peters
mesh_terms: D000367:Age Factors; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant / Q000379:methods / Q000592:standards / Q000706:statistics & numerical data; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy / Q000379:methods / Q000592:standards / Q000706:statistics & numerical data; D032921:Consensus; D057915:Drug Substitution / Q000379:methods / Q000592:standards; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D060046:Maintenance Chemotherapy / Q000592:standards / Q000706:statistics & numerical data; D020360:Neoadjuvant Therapy / Q000379:methods / Q000592:standards / Q000706:statistics & numerical data
chemical_list: D020533:Angiogenesis Inhibitors; D016190:Carboplatin; D002945:Cisplatin
keywords: ESMO; consensus; first line; further lines; non-small-cell lung cancer; second line